FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2333381803> ?p ?o ?g. }

• W2333381803 endingPage "35422" @default.
• W2333381803 startingPage "35412" @default.
• W2333381803 abstract "// Jing-hua Wang 1,2,3,* , Hua Wang 1,2,3,* , Yan-jun Wang 2,3,4,* , Zhong-jun Xia 1,2,3 , Hui-qiang Huang 2,3,5 , Wen-qi Jiang 2,3,5 and Yue Lu 1,2,3 1 Department of Hematological Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China 2 State Key Laboratory of Oncology in South China, Guangzhou, China 3 Collaborative Innovation Center for Cancer Medicine, Guangzhou, China 4 Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China 5 Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China * These authors have contributed equally to this article Correspondence to: Yue Lu, email: // Keywords : extranodal NK/T-cell lymphoma, gemcitabine, oxaliplatin, pegaspargase, adverse effects Received : November 18, 2015 Accepted : March 28, 2016 Published : April 07, 2016 Abstract Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive neoplasm with a poor outcome. Novel L-asparaginase-based treatment regimens, such as GELOX (gemcitabine, oxaliplatin, and L-asparaginase) and P-gemox (gemcitabine, oxaliplatin, and pegaspargase), have shown promising results against stage IE/IIE ENKTL. To define the general applicability of P-gemox, in a retrospective analysis we examined the efficacy and safety of P-gemox in a cohort of 117 patients with newly diagnosed or relapsed/refractory ENKTL. Treatment included 2 to 8 cycles of P-gemox: intravenous gemcitabine (1250 mg/m 2 ) and oxaliplatin (85 mg/m 2 ) and intramuscular pegaspargase (2500 IU/ m 2 ) on day 1 and repeated every 2 weeks, or intravenous gemcitabine (1000 mg/m 2 ) on days 1 and 8 and intravenous oxaliplatin (130 mg/m 2 ) and intramuscular pegaspargase (2500 IU/m 2 ) on day 1 and repeated every 3 weeks. Upon completion of treatment, the overall response rate was 88.8%, and responses were similar for newly diagnosed and relapsed/refractory patients. After a median follow-up of 17 months, the 3-year overall and progression-free survival rates were 72.7% and 57.8%, respectively. Multivariate analysis showed that CR after treatment was the most significant factor affecting survival. P-gemox thus appears to be an effective and well-tolerated treatment for patients with ENKTL." @default.
• W2333381803 created "2016-06-24" @default.
• W2333381803 creator A5021068259 @default.
• W2333381803 creator A5037901329 @default.
• W2333381803 creator A5061864400 @default.
• W2333381803 creator A5062258519 @default.
• W2333381803 creator A5066279146 @default.
• W2333381803 creator A5073325707 @default.
• W2333381803 creator A5083421271 @default.
• W2333381803 date "2016-04-07" @default.
• W2333381803 modified "2023-09-24" @default.
• W2333381803 title "Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma" @default.
• W2333381803 cites W123918382 @default.
• W2333381803 cites W1913362664 @default.
• W2333381803 cites W1954043953 @default.
• W2333381803 cites W1974717295 @default.
• W2333381803 cites W1985239180 @default.
• W2333381803 cites W2011304238 @default.
• W2333381803 cites W2013770941 @default.
• W2333381803 cites W2021326251 @default.
• W2333381803 cites W2022837312 @default.
• W2333381803 cites W2038035645 @default.
• W2333381803 cites W2040222530 @default.
• W2333381803 cites W2040724113 @default.
• W2333381803 cites W2044311824 @default.
• W2333381803 cites W2054344525 @default.
• W2333381803 cites W2064565700 @default.
• W2333381803 cites W2071270987 @default.
• W2333381803 cites W2077126828 @default.
• W2333381803 cites W2082598176 @default.
• W2333381803 cites W2085363831 @default.
• W2333381803 cites W2090821308 @default.
• W2333381803 cites W2094603195 @default.
• W2333381803 cites W2097449310 @default.
• W2333381803 cites W2101879498 @default.
• W2333381803 cites W2107860361 @default.
• W2333381803 cites W2108673054 @default.
• W2333381803 cites W2113282595 @default.
• W2333381803 cites W2123807140 @default.
• W2333381803 cites W2133201432 @default.
• W2333381803 cites W2134315181 @default.
• W2333381803 cites W2160196226 @default.
• W2333381803 cites W2163219205 @default.
• W2333381803 cites W2164520862 @default.
• W2333381803 cites W2168476975 @default.
• W2333381803 cites W2274420705 @default.
• W2333381803 cites W263953935 @default.
• W2333381803 doi "https://doi.org/10.18632/oncotarget.8643" @default.
• W2333381803 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5085239" @default.
• W2333381803 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27072578" @default.
• W2333381803 hasPublicationYear "2016" @default.
• W2333381803 type Work @default.
• W2333381803 sameAs 2333381803 @default.
• W2333381803 citedByCount "34" @default.
• W2333381803 countsByYear W23333818032016 @default.
• W2333381803 countsByYear W23333818032017 @default.
• W2333381803 countsByYear W23333818032018 @default.
• W2333381803 countsByYear W23333818032019 @default.
• W2333381803 countsByYear W23333818032020 @default.
• W2333381803 countsByYear W23333818032021 @default.
• W2333381803 countsByYear W23333818032022 @default.
• W2333381803 countsByYear W23333818032023 @default.
• W2333381803 crossrefType "journal-article" @default.
• W2333381803 hasAuthorship W2333381803A5021068259 @default.
• W2333381803 hasAuthorship W2333381803A5037901329 @default.
• W2333381803 hasAuthorship W2333381803A5061864400 @default.
• W2333381803 hasAuthorship W2333381803A5062258519 @default.
• W2333381803 hasAuthorship W2333381803A5066279146 @default.
• W2333381803 hasAuthorship W2333381803A5073325707 @default.
• W2333381803 hasAuthorship W2333381803A5083421271 @default.
• W2333381803 hasBestOaLocation W23333818031 @default.
• W2333381803 hasConcept C121608353 @default.
• W2333381803 hasConcept C126322002 @default.
• W2333381803 hasConcept C143998085 @default.
• W2333381803 hasConcept C2777589544 @default.
• W2333381803 hasConcept C2779338263 @default.
• W2333381803 hasConcept C2780258809 @default.
• W2333381803 hasConcept C2780962732 @default.
• W2333381803 hasConcept C2781413609 @default.
• W2333381803 hasConcept C526805850 @default.
• W2333381803 hasConcept C71924100 @default.
• W2333381803 hasConcept C90924648 @default.
• W2333381803 hasConceptScore W2333381803C121608353 @default.
• W2333381803 hasConceptScore W2333381803C126322002 @default.
• W2333381803 hasConceptScore W2333381803C143998085 @default.
• W2333381803 hasConceptScore W2333381803C2777589544 @default.
• W2333381803 hasConceptScore W2333381803C2779338263 @default.
• W2333381803 hasConceptScore W2333381803C2780258809 @default.
• W2333381803 hasConceptScore W2333381803C2780962732 @default.
• W2333381803 hasConceptScore W2333381803C2781413609 @default.
• W2333381803 hasConceptScore W2333381803C526805850 @default.
• W2333381803 hasConceptScore W2333381803C71924100 @default.
• W2333381803 hasConceptScore W2333381803C90924648 @default.
• W2333381803 hasIssue "23" @default.
• W2333381803 hasLocation W23333818031 @default.
• W2333381803 hasLocation W23333818032 @default.
• W2333381803 hasLocation W23333818033 @default.
• W2333381803 hasLocation W23333818034 @default.

• next